Grufity logoGrufity logo
Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
HROW

HROW - Harrow Health Inc Stock Price, Fair Value and News

16.79USD+0.63 (+3.90%)Market Closed

Market Summary

HROW
USD16.79+0.63
Market Closed
3.90%

HROW Alerts

  • 1 major insider buys recently.
  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

HROW Stock Price

View Fullscreen

HROW RSI Chart

HROW Valuation

Market Cap

593.7M

Price/Earnings (Trailing)

-18.95

Price/Sales (Trailing)

4.28

EV/EBITDA

-78.6

Price/Free Cashflow

93.21

HROW Price/Sales (Trailing)

HROW Profitability

EBT Margin

-21.88%

Return on Equity

-52.04%

Return on Assets

-10.6%

Free Cashflow Yield

1.07%

HROW Fundamentals

HROW Revenue

Revenue (TTM)

138.7M

Rev. Growth (Yr)

32.5%

Rev. Growth (Qtr)

-4.86%

HROW Earnings

Earnings (TTM)

-31.3M

Earnings Growth (Yr)

-104.2%

Earnings Growth (Qtr)

-48.28%

Breaking Down HROW Revenue

Last 7 days

44.7%

Last 30 days

42.1%

Last 90 days

57.4%

Trailing 12 Months

-19.9%

How does HROW drawdown profile look like?

HROW Financial Health

Current Ratio

3

HROW Investor Care

Shares Dilution (1Y)

17.65%

Diluted EPS (TTM)

-0.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024138.7M000
202392.6M102.7M114.2M130.2M
202279.2M84.3M88.5M88.6M
202152.5M62.6M66.9M72.5M
202050.7M45.2M46.9M48.9M
201944.8M47.9M49.9M51.2M
201830.4M34.1M37.7M41.4M
2017022.4M24.6M26.8M
2016013.1M16.0M19.1M
20153.2M4.5M6.8M9.7M
20142.7M2.3M2.0M1.7M
20133.7M3.3M3.0M0
20120004.0M
Get all data in R, Python etc through our Historical Stock Data APIs
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Harrow Health Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 25, 2024
opaleye management inc.
bought
199,400
9.97
20,000
-
Apr 24, 2024
opaleye management inc.
bought
84,092
10.15
8,285
-
Apr 23, 2024
opaleye management inc.
bought
120,547
10.29
11,715
-
Apr 19, 2024
opaleye management inc.
bought
310,390
10.5575
29,400
-
Mar 28, 2024
opaleye management inc.
bought
641,000
12.82
50,000
-
Mar 22, 2024
baum mark l
bought
104,310
11.59
9,000
chief executive officer
Mar 20, 2024
opaleye management inc.
bought
488,290
9.65
50,600
-
Mar 01, 2024
saharek john p.
acquired
43,750
8.75
5,000
ceo of imprimisrx
Feb 20, 2024
saharek john p.
sold
-134,613
10.67
-12,616
ceo of imprimisrx
Feb 20, 2024
baum mark l
sold
-638,450
10.67
-59,836
chief executive officer

1–10 of 50

Which funds bought or sold HROW recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
VIMA LLC
new
-
2,857
2,857
 -%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-70.03
-521,523
285,795
 -%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-9.89
23,949
395,352
 -%
May 15, 2024
STATE STREET CORP
added
2.8
1,483,920
8,405,970
 -%
May 15, 2024
STANSBERRY ASSET MANAGEMENT, LLC
reduced
-8.38
115,784
1,523,360
 0.21%
May 15, 2024
BRAIDWELL LP
reduced
-91.59
-15,117,600
1,666,540
 0.05%
May 15, 2024
Ophir Asset Management Pty Ltd
reduced
-73.26
-4,199,980
1,939,080
 0.34%
May 15, 2024
Lido Advisors, LLC
unchanged
-
21,315
138,915
 -%
May 15, 2024
PRELUDE CAPITAL MANAGEMENT, LLC
added
18.77
418,615
1,457,400
 0.08%
May 15, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
6.61
45,000
221,000
 -%

1–10 of 44

Are Funds Buying or Selling HROW?

Are funds buying HROW calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HROW
No. of Funds

HROW Alerts

Unveiling Harrow Health Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
kaufman daniel louis
5.43%
1,907,332
SC 13G/A
Feb 13, 2024
vanguard group inc
5.15%
1,808,552
SC 13G
Feb 09, 2024
opaleye management inc.
10.88%
3,820,000
SC 13G/A
Jan 29, 2024
blackrock inc.
6.3%
2,220,538
SC 13G
Jan 09, 2024
private capital management, llc
10.34%
3,630,496
SC 13G
Nov 24, 2023
kaufman daniel louis
5.37%
1,885,032
SC 13G
Aug 18, 2023
baum mark l
9.5%
3,488,361
SC 13D/A
Jan 20, 2023
opaleye management inc.
12.82%
3,775,000
SC 13G/A
Feb 14, 2022
ophir asset management pty ltd
7.08%
1,905,354
SC 13G
Jan 26, 2022
opaleye management inc.
12.2%
3,285
SC 13G/A

Recent SEC filings of Harrow Health Inc

View All Filings
Date Filed Form Type Document
May 13, 2024
10-Q
Quarterly Report
May 13, 2024
8-K
Current Report
Apr 30, 2024
SC 13D/A
13D - Major Acquisition
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
DEFA14A
DEFA14A
Apr 25, 2024
4
Insider Trading
Apr 24, 2024
4
Insider Trading
Apr 19, 2024
4
Insider Trading
Mar 28, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading

Peers (Alternatives to Harrow Health Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
JNJ
372.2B
85.6B
 6.82% -1.69%
9.67
4.35
 5.68% 202.39%
MRK
332.3B
61.4B
 4.65% 15.09%
144.1
5.41
 6.11% -82.30%
AMGN
167.7B
29.5B
 18.35% 39.38%
44.55
5.68
 12.76% -52.47%
PFE
162.3B
57.8B
 12.71% -21.46%
129.52
2.81
 76.51% -86.81%
GILD
84.4B
27.4B
 1.23% -13.37%
174.21
3.07
 1.51% -91.32%
TEVA
18.4B
16.0B
 23.52% 97.09%
-37.29
1.15
 7.23% 71.10%
MID-CAP
ALKS
4.1B
1.7B
 0.67% -19.91%
9.41
2.37
 54.01% 364.56%
PRGO
4.1B
4.6B
 -0.70% -10.77%
-528.11
0.89
 -0.06% 94.55%
BHC
2.5B
9.0B
 -21.94% -21.03%
-5.45
0.28
 10.01% -27.45%
AMPH
2.1B
676.2M
 8.56% -0.82%
13.75
3.14
 30.38% 66.04%
SMALL-CAP
TLRY
1.5B
743.2M
 15.12% -18.85%
-4.35
2.06
 24.65% 80.36%
TXMD
25.8M
1.3M
 18.52% -47.17%
-3.49
19.84
 -98.14% -104.71%
ACRX
18.4M
89.6M
 6.93% 25.60%
-1.29
0.19
 287.27% -129.41%
AGRX
2.5M
21.5M
 2.70% -90.89%
-0.32
0.12
 66.16% 61.83%
ACOR
633.5K
115.7M
 -50.00% -97.38%
0
0.01
 -2.22% -352.48%

Harrow Health Inc News

Latest updates
MarketBeat • 16 May 2024 • 06:08 pm
B. Riley Equities Analysts Cut Earnings Estimates for Harrow, Inc. (NASDAQ:HROW)
MarketBeat • 15 May 2024 • 10:46 pm
Harrow (NASDAQ:HROW) Given New $26.00 Price Target at Craig Hallum
Markets Insider • 20 Mar 2024 • 07:00 am
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre ...
TipRanks • 2 months ago
Harrow Health Inc Unveils Investor Presentation Update.com - TipRanks
American Banking and Market News • 2 months ago
Harrow Health (HROW) Set to Announce Earnings on Tuesday
Seeking Alpha • 6 months ago
Despite Q3 Earnings Miss, Harrow Is Still Appealing For 2024 (NASDAQ:HROW)
CNN • 6 months ago
HROW Stock Quote Price and Forecast
Yahoo Finance • 6 months ago
Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript
TipRanks • 6 months ago
Harrow Health (NASDAQ:HROW) Plummets on Dismal Q3 Print.com - TipRanks
Business Wire • 10 months ago
Harrow Prices $60 Million Public Offering of Common Stock

Harrow Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-4.9%34,58736,35534,26533,47026,10320,32922,82323,32322,12020,18818,71118,13415,44314,59514,3998,06011,81712,60412,75513,51612,290
Gross Profit-4.1%24,03425,05324,19823,47017,83214,16416,10216,78916,15715,10813,76413,71711,67310,65810,7034,8568,1919,0398,6948,2918,392
Operating Expenses3.5%30,96229,92822,45421,11816,62215,94216,19615,09914,05616,86317,4819,5488,7568,0329,1068,0668,8198,11313,0929,0588,948
  S&GA Expenses9.9%28,81326,21221,03319,95715,88815,23915,42114,18513,39812,67211,3569,1238,1647,4418,4366,9548,4167,6898,6088,2488,543
  R&D Expenses-35.6%2,1493,3361,4211,1617347037759146583,9426,125425592591670749403424444810405
EBITDA Margin-632.8%-0.05*-0.01*0.06*-0.01*-0.08*-0.06*-0.15*-0.18*-0.15*-0.15*-0.10*0.14*0.18*--------
Interest Expenses5.7%5,4155,1245,7495,7044,7471,8581,8001,7941,7921,9241,6851,314513-2,734498-505-560-561-620-716-603
Income Taxes100.0%--5351,539-15.00-288-35.0040.00-------------
Earnings Before Taxes-40.1%-13,565-9,683-2,852-4,244-6,9311,055-6,429-6,199-2,438-7,285-8,328-2,4782171,1458,623-260-12,9232,600-11,630-2,42011,333
EBT Margin-20.2%-0.22*-0.18*-0.11*-0.16*-0.20*-0.16*-0.25*-0.29*-0.26*-0.25*-0.14*0.12*0.19*--------
Net Income-48.3%-13,565-9,148-4,391-4,229-6,6431,055-6,464-6,239-2,438-7,418-8,328-2,4782171,1498,638-237-12,9072,657-11,469-2,37811,358
Net Income Margin-20.5%-0.23*-0.19*-0.12*-0.16*-0.20*-0.16*-0.26*-0.29*-0.26*-0.25*-0.14*0.12*0.19*--------
Free Cashflow-155.5%-4,7208,502-1,7284,316-8,710-4,590-1,4654,600563-1,627-2,3654,2912,997--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-5.3%29631228622421715799.0098.0098.0098.0010310756.0057.0059.0049.0047.0059.0055.0065.0067.00
  Current Assets-10.1%12513911060.0052.0011864.0065.0062.0061.0091.0093.0041.0041.0041.0030.0026.0036.0032.0038.0039.00
    Cash Equivalents-7.5%69.0074.0066.0023.0019.0096.0045.0046.0042.0042.0058.0073.006.004.006.004.004.005.004.004.004.00
  Inventory-0.5%11.0011.009.009.009.007.005.005.004.004.004.004.004.004.004.004.004.003.002.003.002.00
  Net PPE-3.7%3.004.004.004.004.003.003.003.003.003.005.005.004.004.005.005.005.005.005.006.006.00
  Goodwill0%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.002.002.00
Liabilities-2.7%23524221120219613098.0093.0088.0087.0087.0084.0028.0031.0035.0034.0032.0032.0031.0030.0029.00
  Current Liabilities-15.4%42.0049.0019.0023.0018.0019.0018.0013.009.0010.0010.008.0010.0011.0014.0013.0013.0012.0011.0010.0011.00
Shareholder's Equity-14.9%60.0071.0076.0022.0022.0028.001.005.0010.0011.0016.0023.0028.0027.0025.0015.0015.0027.0024.0035.0037.00
  Retained Earnings-10.1%-147-133-124-120-116-109-110-104-97.84-95.41-87.99-79.66-77.18-77.40-78.55-87.19-86.95-74.04-76.70-65.23-62.85
  Additional Paid-In Capital1.6%208205200143138137112110108107105103105105104103102102101100100
Shares Outstanding0.6%35.0035.0035.0030.0030.0030.0027.0027.0027.0027.0027.0026.0026.00--------
Minority Interest0%-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.35-0.33-0.31-0.29-0.23-0.07-0.02
Float----464---159---196---125---205-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-153.2%-4,6288,696-1,2084,566-8,214-3,712-4104,860967-1,490-2,0765,4403,208-5662,667-2,651-5501,652-70.00844-1,476
  Share Based Compensation-33.7%4,1696,2873745,2901,6333,0082411,7352,0163,4882.0028.008551,098559268533513169262713
Cashflow From Investing45.8%-110-203-20,131-1,249-130,970-5.00-1,069-259-410-14,197-12,9348,669-224-90.00-281-337-273-969-79.00-461-324
Cashflow From Financing-4394.4%-809-18.0064,19518962,16255,028--111-776-2.0015.0052,238-781-770-7612,966-2.00635-413-455-773
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

HROW Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 34,587,000$ 26,103,000
Cost of sales(10,553,000)(8,271,000)
Gross profit24,034,00017,832,000
Operating expenses:  
Selling, general and administrative28,813,00015,888,000
Research and development2,149,000734,000
Total operating expenses30,962,00016,622,000
(Loss)income from operations(6,928,000)1,210,000
Other (expense) income:  
Interest expense, net(5,415,000)(4,747,000)
Investment (loss) gain from Eton Pharmaceuticals(1,248,000)2,042,000
Loss on extinguishment of debt(5,465,000)
Other income, net26,00029,000
Total other expense, net(6,637,000)(8,141,000)
Loss before income tax expense(13,565,000)(6,931,000)
Income tax benefit288,000
Net loss$ (13,565,000)$ (6,643,000)
Basic net loss per share of common stock$ (0.38)$ (0.22)
Diluted net loss per share of common stock$ (0.38)$ (0.22)
Weighted average number of shares of common stock outstanding, basic35,469,63830,289,730
Weighted average number of shares of common stock outstanding, diluted35,469,63830,289,730
Product Sales Net [Member]  
Revenues:  
Total revenues$ 34,508,000$ 20,453,000
Other Revenues [Member]  
Revenues:  
Total revenues$ 79,000$ 5,650,000

HROW Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 68,538,000$ 74,085,000
Investment in Eton Pharmaceuticals7,433,0008,681,000
Accounts receivable, net28,960,00037,271,000
Inventories10,810,00010,867,000
Prepaid expenses and other current assets9,717,0009,588,000
Total current assets125,458,000140,492,000
Property, plant and equipment, net3,389,0003,521,000
Capitalized software costs, net2,019,0002,138,000
Operating lease right-of-use assets, net6,968,0006,785,000
Intangible assets, net157,370,000159,906,000
Goodwill332,000332,000
TOTAL ASSETS295,536,000313,174,000
Current liabilities  
Accounts payable and accrued expenses15,129,00024,581,000
Accrued rebates and copay assistance20,690,00019,442,000
Accrued payroll and related liabilities5,027,0005,450,000
Deferred revenue and customer deposits112,00075,000
Current portion of operating lease obligations795,000806,000
Total current liabilities41,753,00050,354,000
Operating lease obligations, net of current portion6,716,0006,524,000
Accrued expenses, net of current portion2,713,0002,713,000
Notes payable, net of unamortized debt discount184,148,000183,172,000
TOTAL LIABILITIES235,330,000242,763,000
Commitments and contingencies
STOCKHOLDERS’ EQUITY  
Common stock, $0.001 par value, 50,000,000 shares authorized, 35,380,955 and 35,168,260 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively35,00035,000
Additional paid-in capital207,995,000204,635,000
Accumulated deficit(147,469,000)(133,904,000)
TOTAL HARROW, INC. STOCKHOLDERS’ EQUITY60,561,00070,766,000
Noncontrolling interests(355,000)(355,000)
TOTAL STOCKHOLDERS’ EQUITY60,206,00070,411,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 295,536,000$ 313,174,000

About Harrow Health Inc

HROW
Harrow Health, Inc., an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
 CEO
 WEBSITEharrowinc.com
 INDUSTRYPharmaceuticals
 EMPLOYEES217

Harrow Health Inc Frequently Asked Questions

What is the ticker symbol for Harrow Health Inc? What does HROW stand for in stocks?

HROW is the stock ticker symbol of Harrow Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Harrow Health Inc (HROW)?

As of Fri May 17 2024, market cap of Harrow Health Inc is 593.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HROW stock?

You can check HROW's fair value in chart for subscribers.

What is the fair value of HROW stock?

You can check HROW's fair value in chart for subscribers. The fair value of Harrow Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Harrow Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HROW so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Harrow Health Inc a good stock to buy?

The fair value guage provides a quick view whether HROW is over valued or under valued. Whether Harrow Health Inc is cheap or expensive depends on the assumptions which impact Harrow Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HROW.

What is Harrow Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HROW's PE ratio (Price to Earnings) is -18.95 and Price to Sales (PS) ratio is 4.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HROW PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Harrow Health Inc's stock?

In the past 10 years, Harrow Health Inc has provided 0.115 (multiply by 100 for percentage) rate of return.